Atea PharmaceuticalsI Stock Analysis

AVIR
 Stock
  

USD 4.65  0.02  0.43%   

The big decline in price over the last few months for Atea PharmaceuticalsInc could raise concerns from retail investors as the firm is trading at a share price of 4.65 on 195,066 in volume. The company executives failed to add value to investors and position the firm supply of money to exploit market volatility in November. However, diversifying your holdings with Atea PharmaceuticalsInc or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.54. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Atea PharmaceuticalsI partners.
Please continue to Trending Equities.
  
The Atea PharmaceuticalsI stock analysis report makes it easy to digest most publicly released information about Atea PharmaceuticalsI and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Atea PharmaceuticalsI Stock analysis module also helps to analyze the Atea PharmaceuticalsI price relationship with some important fundamental indicators such as market cap and management efficiency.

Atea PharmaceuticalsI Stock Analysis Notes

About 70.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.6. Some equities with similar Price to Book (P/B) outperform the market in the long run. Atea PharmaceuticalsInc last dividend was issued on the 9th of November 2012. The entity had 1:6 split on the 9th of November 2012. Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 63 people. For more info on Atea PharmaceuticalsInc please contact Joseph Patti at 857 284 8891 or go to https://ateapharma.com.

Atea PharmaceuticalsInc Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Atea PharmaceuticalsI's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Atea PharmaceuticalsInc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Atea PharmaceuticalsI generated a negative expected return over the last 90 days
Atea PharmaceuticalsI has high historical volatility and very poor performance
Atea PharmaceuticalsInc currently holds about 684.48 M in cash with (87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Atea PharmaceuticalsI has a poor financial position based on the latest SEC disclosures
Roughly 70.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Atea Pharmaceuticals Insider Trades Send a Signal - Atea Pharmaceuticals - Benzinga

Atea PharmaceuticalsInc Upcoming and Recent Events

Earnings reports are used by Atea PharmaceuticalsI to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Atea PharmaceuticalsI previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report29th of March 2022
Next Financial Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End29th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Atea PharmaceuticalsI Largest EPS Surprises

Earnings surprises can significantly impact Atea PharmaceuticalsI's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-12
2021-06-300.010.020.01100 
2022-05-10
2022-03-31-0.58-0.510.0712 
2022-08-08
2022-06-30-0.52-0.380.1426 
View All Earnings Estimates

Atea PharmaceuticalsI SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Atea PharmaceuticalsI prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Atea PharmaceuticalsI investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Atea PharmaceuticalsInc specific information freely available to individual and institutional investors to make a timely investment decision.
8th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
21st of June 2022
Submission of Matters to a Vote of Security Holders
View
10th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
28th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
16th of February 2022
Unclassified Corporate Event
View
14th of February 2022
Unclassified Corporate Event
View
10th of February 2022
Unclassified Corporate Event
View
9th of February 2022
Unclassified Corporate Event
View

Atea PharmaceuticalsI Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 388.95 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Atea PharmaceuticalsI's market, we take the total number of its shares issued and multiply it by Atea PharmaceuticalsI's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Atea PharmaceuticalsI Profitablity

Atea PharmaceuticalsI's profitability indicators refer to fundamental financial ratios that showcase Atea PharmaceuticalsI's ability to generate income relative to its revenue or operating costs. If, let's say, Atea PharmaceuticalsI is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Atea PharmaceuticalsI's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Atea PharmaceuticalsI's profitability requires more research than a typical breakdown of Atea PharmaceuticalsI's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.19 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.16 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.0.
Last ReportedProjected for 2022
Return on Investment(18.80) (20.28) 
Return on Average Assets(4.92) (5.31) 
Return on Average Equity(8.73) (9.42) 
Return on Invested Capital(0.72) (0.74) 
Return on Sales 0.39  0.42 

Management Efficiency

The entity has return on total asset (ROA) of 0.0249 % which means that it generated profit of $0.0249 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.0573 %, meaning that it created $0.0573 on every $100 dollars invested by stockholders. Atea PharmaceuticalsI management efficiency ratios could be used to measure how well atea pharmaceuticalsinc manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/06/2022, Return on Sales is likely to grow to 0.42, while Return on Investment is likely to drop (20.28) . Atea PharmaceuticalsI Revenue to Assets are relatively stable at the moment as compared to the past year. Atea PharmaceuticalsI reported last year Revenue to Assets of 0.17. As of 12/06/2022, Total Assets Per Share is likely to grow to 2.77, while Current Assets are likely to drop slightly above 105.1 M.
Last ReportedProjected for 2022
Book Value per Share 8.57  8.20 
Enterprise Value over EBIT(1.00) (1.08) 
Enterprise Value over EBITDA(0.70) (0.75) 
Price to Book Value 1.05  1.07 
Tangible Assets Book Value per Share 9.33  12.87 
Enterprise Value-96.7 M-99.3 M
Tangible Asset Value772.9 M651.9 M

Technical Drivers

As of the 6th of December, Atea PharmaceuticalsI shows the mean deviation of 2.63, and Risk Adjusted Performance of (0.27). Atea PharmaceuticalsInc technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Atea PharmaceuticalsInc, which can be compared to its rivals. Please confirm Atea PharmaceuticalsInc standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Atea PharmaceuticalsInc is priced correctly, providing market reflects its regular price of 4.65 per share. Given that Atea PharmaceuticalsI has jensen alpha of (0.76), we suggest you to validate Atea PharmaceuticalsInc's prevailing market performance to make sure the company can sustain itself at a future point.

Atea PharmaceuticalsInc Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Mid-point over period is an average of Atea PharmaceuticalsInc highest and lowest values attained during the given period.
.

Atea PharmaceuticalsInc Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atea PharmaceuticalsI insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atea PharmaceuticalsI's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atea PharmaceuticalsI insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Atea PharmaceuticalsI Predictive Daily Indicators

Atea PharmaceuticalsI intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Atea PharmaceuticalsI stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Atea PharmaceuticalsI Forecast Models

Atea PharmaceuticalsI time-series forecasting models is one of many Atea PharmaceuticalsI's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Atea PharmaceuticalsI's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Atea PharmaceuticalsI Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Atea PharmaceuticalsI prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Atea PharmaceuticalsI shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Atea PharmaceuticalsI. By using and applying Atea PharmaceuticalsI Stock analysis, traders can create a robust methodology for identifying Atea PharmaceuticalsI entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(75.66) (81.63) 
EBITDA Margin(73.82) (79.65) 
Gross Margin 103.66  91.28 
Profit Margin(35.12) (37.89) 

Current Atea PharmaceuticalsI Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Atea PharmaceuticalsI analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Atea PharmaceuticalsI analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
9.33Hold3Odds
Atea PharmaceuticalsInc current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Atea PharmaceuticalsI analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Atea PharmaceuticalsI stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Atea PharmaceuticalsInc, talking to its executives and customers, or listening to Atea PharmaceuticalsI conference calls.
Atea PharmaceuticalsI Analyst Advice Details

Atea PharmaceuticalsI Stock Analysis Indicators

Atea PharmaceuticalsInc stock analysis indicators help investors evaluate how Atea PharmaceuticalsI stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Atea PharmaceuticalsI shares will generate the highest return on investment. By understating and applying Atea PharmaceuticalsI stock analysis, traders can identify Atea PharmaceuticalsI position entry and exit signals to maximize returns.
Begin Period Cash Flow850224000.00
Common Stock Shares Outstanding21592441.00
Total Stockholder Equity710077000.00
Total Cashflows From Investing Activities-4000.00
Tax Provision17400000.00
Quarterly Earnings Growth Y O Y2.641
Property Plant And Equipment Net23000.00
Retained Earnings56030000.00
Cash And Short Term Investments764375000.00
Retained Earnings Total Equity56030000.00
Cash764375000.00
CodeAVIR
Accounts Payable4534000.00
Net Debt-764375000.00
50 Day M A5.3292
Total Current Liabilities56883000.00
Currency CodeUSD
Non Current Assets Total489000.00
Common Stock Total Equity83000.00
Non Currrent Assets Other466000.00
Please continue to Trending Equities. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for analysis

When running Atea PharmaceuticalsInc price analysis, check to measure Atea PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea PharmaceuticalsI is operating at the current time. Most of Atea PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Atea PharmaceuticalsI's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Atea PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Is Atea PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atea PharmaceuticalsI. If investors know Atea PharmaceuticalsI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atea PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
2.64
Market Capitalization
389 M
Quarterly Revenue Growth YOY
2.95
Return On Assets
0.0249
Return On Equity
0.0573
The market value of Atea PharmaceuticalsInc is measured differently than its book value, which is the value of Atea PharmaceuticalsI that is recorded on the company's balance sheet. Investors also form their own opinion of Atea PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Atea PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Atea PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine Atea PharmaceuticalsI value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.